Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics entities : Orange save search
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2024-04-24 (Crawled : 17:00) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: 0.0%
presentation for meeting therapeutics
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K
|
Health Technology
|
| O: -0.93%
H: 7.04%
C: 0.94%
fda meeting hypertension therapeutics
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
Published: 2024-03-15 (Crawled : 11:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: -1.74%
H: 2.13%
C: -4.96%
patent grant therapeutics
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Published: 2024-03-14 (Crawled : 12:00) - prnewswire.com
INTS | $3.935 -2.84% -2.92% 4.1K
|
|
| O: 0.0%
H: 5.37%
C: 1.46%
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -0.35%
H: 0.0%
C: 0.0%
conference therapeutics
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Published: 2024-03-12 (Crawled : 11:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: 13.79%
H: 0.0%
C: -16.06%
year therapeutics financial results
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: 2.2%
H: 1.21%
C: -0.85%
tumors authorization treatment application therapeutics
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
Published: 2024-02-05 (Crawled : 12:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: 9.48%
H: 15.37%
C: 10.75%
patent disease alzheimer’s application therapeutics
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: -1.58%
H: 11.22%
C: 11.16%
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 0.36%
H: 3.65%
C: 3.35%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.5%
H: 3.18%
C: 3.12%
conference therapeutics
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
lyn-005 positive schizophrenia therapeutics study
Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
Published: 2024-01-03 (Crawled : 18:00) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.72%
H: 0.55%
C: -1.71%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.21%
H: 0.01%
C: -1.8%
spinraza first system therapeutics study
Lyndra Therapeutics Raises $101 Million in Series E Funding
Published: 2023-12-21 (Crawled : 15:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.29%
H: 0.76%
C: 0.14%
million series therapeutics funding
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
Published: 2023-11-27 (Crawled : 23:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: 10.74%
H: 16.83%
C: 7.17%
fda approval tumors treatment therapeutics
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: -35.39%
H: 19.38%
C: 18.54%
fda update trial therapeutics financial results
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 4.34%
H: 0.0%
C: 0.0%
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 1.13%
H: 1.36%
C: -1.45%
disease alzheimer’s global therapeutics
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Published: 2023-10-10 (Crawled : 20:00) - prnewswire.com
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 1.32%
H: 1.48%
C: -5.13%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: -1.88%
vk2735 obesityweek agonist presentation trial therapeutics
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
Published: 2023-10-04 (Crawled : 11:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: -2.56%
H: 35.96%
C: 16.23%
update expansion therapeutics
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
FOLD 4 | $10.52 -1.77% -1.81% 1.6M
|
Health Technology
|
| O: -4.33%
H: 12.04%
C: 11.95%
therapeutics financial results
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 4.62%
H: 0.0%
C: -1.54%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.67%
H: 1.42%
C: 1.06%
update trial therapeutics
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
Published: 2023-06-07 (Crawled : 12:00) - biospace.com/
COYA | News | $8.28 3.24% 3.14% 120K
|
|
| O: 5.76%
H: 5.01%
C: 2.4%
disease biomarker alzheimer’s treatment blood imaging therapeutics
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
Published: 2023-05-11 (Crawled : 20:00) - prnewswire.com
TRVI | $2.68 -5.97% -6.34% 120K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: -5.35%
business update therapeutics financial results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.